This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bio Vitos Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BIOVIT?
Owner Type	Number of Shares	Ownership Percentage
Institutions	765,571	1.94%
Public Companies	2,798,344	7.1%
Individual Insiders	3,615,483	9.18%
Private Companies	15,938,780	40.5%
General Public	16,283,916	41.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 34%.

Top Shareholders

Top 11 shareholders own 58.67% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.7%	Andra Februari AB	7,762,557	SEK 931.5k	0%	no data
16.1%	BIO Vitos Norge AS	6,351,732	SEK 762.2k	0%	no data
7.1%	Double Bond Pharmaceutical International AB (publ)	2,798,344	SEK 335.8k	0%	no data
6.33%	Ann Carnefeldt Crogh	2,492,405	SEK 299.1k	0%	no data
2.54%	Norvolt As	1,000,000	SEK 120.0k	0%	no data
2.09%	StrÖMsnÄS HerrgÅRd Ab	824,491	SEK 98.9k	0%	no data
2.08%	Morten Skjonberg	819,902	SEK 98.4k	0%	no data
1.93%	UBS Asset Management AG	760,002	SEK 91.2k	0%	no data
0.75%	Jesper Birgemo	294,021	SEK 35.3k	0%	no data
0.023%	Joen Averstad	9,155	SEK 1.1k	0%	no data
0.014%	FCG Fonder AB	5,569	SEK 668.1	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/14 01:20
End of Day Share Price	2025/04/11 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio Vitos Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.